Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
spondyloarthritis
Marketing
AbbVie touts more Rinvoq data with key FDA decisions pending
Rinvoq has hit its goal in no-radiographic axial spondyloarthritis as an FDA decision for ankylosing spondylitis remains unforthcoming.
Angus Liu
Oct 7, 2021 10:29am
Novartis' Cosentyx nabs FDA approval in spondyloarthritis
Jun 16, 2020 9:25pm
AbbVie's Skyrizi bests Cosentyx in head-to-head psoriasis trial
Jun 15, 2020 10:47am
Novartis' Cosentyx chases recent Taltz nod with long-term data
Jun 4, 2020 10:27am
Lilly's Taltz outpaces Novartis' Cosentyx with 4th FDA approval
Jun 1, 2020 6:45am
Novartis' Cosentyx, Lilly's Taltz face off in spondyloarthritis
Nov 12, 2019 11:20am
